Clopidogrel versus Prasugrel in dual Platelet inhibition on elderly patients with acute coronary syndrome – the CLOPRA study

Main Article Content

Joerg Piper http://orcid.org/0000-0002-0234-788X Ruediger Walscheid Linda Tennant

Abstract

Our study carried out in elderly and multimorbid patients with acute coronary syndrome initially treated with ASS (100 mg per day) plus Clopidogrel (75 mg per day) was focused at Clopidogrel low- and non-responders and potential Clopidogrel-drug interactions. Moreover, we intended to clarify how far patients with reduced Clopidogrel response can profit by switching to Prasugrel.

In 178 patients (mean age: 74.1 ± 0.6 years) Thrombocyte Reactivity Indices (TRI) were measured by VASP-tests. Patients showing a limited Clopidogrel response (low- and non-responders) were switched to Prasugrel (60 mg loading dose followed by 5 or 10 mg maintenance dose per day; 10 mg as standard dose, 5 mg in patients aged 75 years or older or weighting 60 Kg or less). Patients who were switched to Prasugrel were controlled by further VASP-tests. Additional evaluations were made for several subgroups of different age and gender.

In elderly patients the fraction of Clopidogrel low- and non-responders tended to higher proportions than in younger patients (34.8 versus 46.8 %). In all cases with limited Clopidogrel response thrombocyte reactivity could be lowered by switching to Prasugrel. In patients of 75 years or older, or weighting less than 60 KG, a daily dose of 5 mg Prasugrel led to the same sufficient reduction of thrombocyte reactivity as in the other patients given 10 mg per day. After drug-switching circa 6 % remained low- or non responders regardless of whether they were treated with 5 or 10 mg Prasugrel. In patients successfully switched to Prasugrel we found the same reduction of thrombocyte reactivity as in Clopidogrel responders (mean TRI: 19%); all of our patients treated as described were free from any bleeding complications. Beside other drugs especially beta blockers seemed to be associated with significantly reduced Clopidogrel response, whereas proton pump inhibitors showed no interaction.

All in all, Prasugrel seems to be more effective in lowering thrombocyte reactivity also in elderly patients, because the proportion of patients with limited response is much lower than in patients treated with Clopidogrel.

Article Details

How to Cite
PIPER, Joerg; WALSCHEID, Ruediger; TENNANT, Linda. Clopidogrel versus Prasugrel in dual Platelet inhibition on elderly patients with acute coronary syndrome – the CLOPRA study. Medical Research Archives, [S.l.], v. 2, n. 1, aug. 2015. ISSN 2375-1924. Available at: <http://journals.ke-i.org/index.php/mra/article/view/343>. Date accessed: 19 sep. 2017. doi: https://doi.org/10.18103/mra.v2i1.343.
Keywords
Clopidogrel; Prasugrel; acute coronary syndrome; ACS; elderly patients; responders; non responders; VASP-test; thrombocyte reactivity index; TRI; drug interactions
Section
Research Articles

References

References

(1) Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Thromb Haemost 2005; 3: 85–92

(2) Bassand JP. Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy. EUR Heart J 2006; Supplement G: 35-37

(3) Bates ER, Lau WC, Angiolillo DJ.: Clopidogrel-drug interactions.
J Am Coll Cardiol. 2011; 15; 57(11):1251-63

(4) Bernlochner I, Mayer K, Morath T, Orban M, Schulz S, Schomig A, Braun S, Kastrati. A, Sibbing D. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronar stenting. Thromb. Haemost. 2013; 109 / 3: 361-567

(5) Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P. Verify Now and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
Platelets 2010; 21(2): 94-100

(6) Bonello L, Armero S, Ait Mokhtar O, Mancini J, Aldebert P, Saut N, Bonello N, Barragan P, Arques S, Giacomoni MP, Bonello-Burignat C, Bartholomei MN, Dignat-George F, Camoin-Jau L, Paganelli F.
Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
J Am Coll Cardiol 2010 b; 56: 1630–1636

(7) Bonello L, Paganelli F, Arpin-Bornert M, Auquier P, Samprol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilatator-stimulated phorphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.
J. Thromb. Haemost. 2007; 5: 1630-1636

(8) Bonello L, Tantry U., Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings IK, Keraiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010 a; 56(12): 919-933

(9) Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A com¬parison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibi¬tion is related to active metabolite formation. Am Heart J 2007; 153(1)/66: e9–16

(10) Bouman HJ, Parlak JW, van Werkum W, Breet NJ, ten Cate H, Hackeng CM, Ten Berg, JM, Taubert D. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
J. Thromb. Haemost 2010; 8: 482-488

(11) Breet NJ, van Werkum JW, Bouman HJ, Kkelder JC, Ruven HJT, Bal ET, DEneer VH, Harmsze AM, van der Heyden JAS, Rensing BJWM, Suttorp MJ, Hackeng, CM., ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303(8): 754-762

(12) Erlinge D, Gurbel PA, James S, Lindahl TL, Svensson P, Ten Berg JM, Foley DP, Wagner H, Brown PB, Luo J, Zhou Ch, Moser BA, Jakubowski JA, Small D, Winters K, Angiolillo DJ. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
J Am Coll Cardiol 2013; 62 (7): 577-583

(13) Gaglia MA Jr, Waksman R.: Proton pump inhibitors and clopidogrel.
Cardiovasc The. 2010; 28(3): 169-76

(14) Geisler T, Langer H, Wydymus M, Zürn Ch, Göhring K, May A, Gawaz M. Low response to Clopidogrel is Associated with Cardiovascular Outcome after Coronary Stent Implantation. Eur Heart J 2006; 27(20): 2420-2425

(15) Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908–2913

(16) Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZR, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.
J. Am. Coll Cardiol 2005; 46: 1827-1832

(17) Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145(2): 239-247

(18) Harrison P, Frelinger AL, Furmann MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thrombosis Research 2007; 120: 323-336

(19) Herrath D, Ludwig WD, Thimme W. Dual anti platelet therapy – time for drug monitoring? Arzneimittelbrief (AMB) 2011; 45: 33 (in German)

(20) Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov
I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Circulation 2004; 109(25): 3171-3175

(21) Mega JL1, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel 38 - Thrombolysis In Myocardial Infarction 38). N Engl J Med 2009; 360: 354.

(22) Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR,
Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to
inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107: 32–37

(23) Michelson AD. Methods for the measurement of platelet function.
Am J Cardiol 2009; 103 (suppl.): 20A-26A

(24) Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol. 2004; 93(4): 456-458

(25) Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antonucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.
J Thromb Hemost 2007; 5: 1839-1847

(26) Schrör K, Kirch W. New anti platelet drugs in clinic and practice. Schattauer, 2013, ISBN: 978-3-7845-2926-I, pp. 81-85 (in German)

(27) Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145–1152

(28) Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45(2):246-51

(29) Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis.
Arch Intern Med. 2007;167(15): 1593-1599

(30) Varenhorst Ch, James S, Erlinge D, Brandt JT, O´Braun O, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close, SL. Genetic variation of CYP2C19 affects both pharma-cokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in ASS-treated pa¬tients with coronary artery disease. Eur Heart J 2009; 30(14):1744–1752

(31) Wiviott SD, Antmann EM, Braunwald E. Prasugrel. Circulation 2010; 122: 394-403

(32) Wiviott SD, Braunwald E, McCabe CH, Montelescort G, Ruzyllo W, Gottlieb S, Neumabnn FJ, rdissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakody G, Gibson CM, Antmann EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.